Dose-Dense Therapy in Aggressive Lymphoma

Expanded access No longer available Study Group of Medical Tumour Therapy (AGMT)

Summary

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Timeline

Start: —
Primary completion: —
Completion: —

Outcome

Met primary endpoint

paper Overall survival at 3 years was 0.766 (95% CI 0.6247, 0.8598) in the dose-dense arm and 0.462 PMID 19693500 ↗

paper Dose-dense therapy with CEOP/IMVP-Dexa is feasible and resulted in an absolute increase of 34% in the survival probability compared to CHOP PMID 19693500 ↗

Publications

Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Epirubicin	Small molecule	70 mg/m2	Intravenous
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous
Subject	Ifosfamide	Small molecule	2000 mg/m2	Intravenous
Subject	Methotrexate	Small molecule	800 mg/m2	Intravenous
Subject	Prednisolone	Other / unclassified	100 mg	Oral
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	—
Background	Calcium folinate	Unknown	—	—
Background	filgrastim	Protein / enzyme biologic	—	—